GlassScriptPhysician profile
Julie Levitt
NPI 1215991807
$1,944.91
in general payments reported to CMS, 2019-2025
23 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $134 · 2021: $424 · 2022: $413 · 2023: $220 · 2024: $249 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.67 | 2019-2024 | |
| Allergan, INC. | $120.02 | 2019-2022 | |
| Pfizer INC. | $114.53 | 2022-2025 | |
| Organon LLC | $114.22 | 2024-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $96.80 | 2019-2025 | |
| Hologic Sales and Service, LLC | $87.08 | 2019-2025 | Myosure Tissue Removal Device, Aptima, Omni Hysteroscope |
| Exeltis, USA INC. | $74.50 | 2019-2023 | Slynd |
| Amag Pharmaceuticals, INC. | $66.92 | 2019-2020 | |
| Coopersurgical, INC. | $51.06 | 2019-2022 | |
| Millicent US INC | $41.75 | 2024-2025 | Intrarosa, Femring |
| Vertical Pharmaceuticals, LLC | $31.91 | 2019 | |
| Gynesonics, INC. | $26.86 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Merck Sharp & Dohme LLC | $25.28 | 2019 | |
| Medtronic, INC. | $22.66 | 2023 | Truclear |
| Alexion Pharmaceuticals, INC. | $18.87 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $17.35 | 2022 | |
| Therapeuticsmd, INC. | $15.95 | 2019 | |
| Lupin INC. | $13.93 | 2019 | |
| Novo Nordisk INC | $13.87 | 2023 | Wegovy |
| Minerva Surgical, INC | $13.01 | 2023 | |
| Avion Pharmaceuticals | $12.41 | 2021 | |
| Agile Therapeutics, INC. | $11.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.